Verastem, Inc. (VSTM) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Veristem Oncology's fourth quarter and full year 2025 earnings conference call. My name is Desiree and I will be your call operator today. Please note this event is being recorded. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. I will now turn the call over to Julissa Viana, Vice President of Corporate Communications, Investor Relations, and Patient Advocacy at Veristem Oncology. Please go ahead. Thank you, operator. Welcome, everyone, and thank you for joining us today to discuss Verisim's fourth quarter and full year 2025 financial results and recent business updates. This afternoon, we issued a press release detailing these results, along with a slide presentation that we will reference during our call today. Both are available on the investor relations section of our website. Before we begin, let me point out that we'll be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Additionally, today, we'll be discussing certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are provided in the press release we issued today. Joining me on today's call to deliver prepared remarks and take your questions are Dan Patterson, President and Chief Executive Officer, Mike Crowther, Chief Commercial Officer, Dr. Michael Kaufman, President of Development, and Dan Calkins, Chief Financial Officer. I will now turn the call over to Dan. Thank you, Delisa. Good afternoon, and thanks for joining our ...